DE2818922A1 - Verbesserte impfstoffe mit gehalt an kapselpolysacchariden - Google Patents
Verbesserte impfstoffe mit gehalt an kapselpolysaccharidenInfo
- Publication number
- DE2818922A1 DE2818922A1 DE19782818922 DE2818922A DE2818922A1 DE 2818922 A1 DE2818922 A1 DE 2818922A1 DE 19782818922 DE19782818922 DE 19782818922 DE 2818922 A DE2818922 A DE 2818922A DE 2818922 A1 DE2818922 A1 DE 2818922A1
- Authority
- DE
- Germany
- Prior art keywords
- capsular polysaccharides
- ribosomes
- pneumoniae
- diplococcus
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229920001282 polysaccharide Polymers 0.000 title claims description 57
- 239000005017 polysaccharide Substances 0.000 title claims description 57
- 150000004676 glycans Chemical class 0.000 title claims description 56
- 229960005486 vaccine Drugs 0.000 title claims description 31
- 210000003705 ribosome Anatomy 0.000 claims description 42
- 229920002477 rna polymer Polymers 0.000 claims description 17
- 239000002775 capsule Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 13
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 12
- 241000606768 Haemophilus influenzae Species 0.000 claims description 9
- 230000001580 bacterial effect Effects 0.000 claims description 9
- 239000002244 precipitate Substances 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 238000001556 precipitation Methods 0.000 claims description 6
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 5
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- 229940047650 haemophilus influenzae Drugs 0.000 claims description 5
- -1 cetylpyridinium polysaccharide Chemical class 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 3
- 229960004830 cetylpyridinium Drugs 0.000 claims 1
- 239000012266 salt solution Substances 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
- 241000193998 Streptococcus pneumoniae Species 0.000 description 27
- 238000005119 centrifugation Methods 0.000 description 21
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 239000000872 buffer Substances 0.000 description 13
- 235000019441 ethanol Nutrition 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 11
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 11
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 7
- 238000000855 fermentation Methods 0.000 description 7
- 230000004151 fermentation Effects 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 241000588748 Klebsiella Species 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000012133 immunoprecipitate Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000000951 immunodiffusion Effects 0.000 description 3
- 230000033764 rhythmic process Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 230000003497 anti-pneumococcal effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940124733 pneumococcal vaccine Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 235000015842 Hesperis Nutrition 0.000 description 1
- 235000012633 Iberis amara Nutrition 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000001727 anti-capsular Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000009655 industrial fermentation Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0266—Klebsiella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7713009A FR2388563A1 (fr) | 1977-04-29 | 1977-04-29 | Vaccins acellulaires perfectionnes contenant des polysaccharides capsulaires |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2818922A1 true DE2818922A1 (de) | 1978-11-09 |
Family
ID=9190107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19782818922 Withdrawn DE2818922A1 (de) | 1977-04-29 | 1978-04-28 | Verbesserte impfstoffe mit gehalt an kapselpolysacchariden |
Country Status (10)
| Country | Link |
|---|---|
| JP (1) | JPS53136516A (es) |
| BE (1) | BE866464A (es) |
| CA (1) | CA1103155A (es) |
| CH (1) | CH630806A5 (es) |
| DE (1) | DE2818922A1 (es) |
| ES (1) | ES469225A1 (es) |
| FR (1) | FR2388563A1 (es) |
| GB (1) | GB1603340A (es) |
| IT (1) | IT1156717B (es) |
| NL (1) | NL7804660A (es) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4141970A1 (de) * | 1991-12-16 | 1993-06-17 | Charite Med Fakultaet | Kombinationsimpfstoff gegen aids, bilharziose und tuberkulose und verfahren zu seiner herstellung |
| WO1997030171A1 (en) * | 1996-02-14 | 1997-08-21 | Merck & Co., Inc. | Polysaccharide precipitation process |
| US6410025B1 (en) | 1996-02-14 | 2002-06-25 | Merck & Co., Inc. | Polysaccharide precipitation process |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1115210A (en) * | 1977-11-28 | 1981-12-29 | Dennis J. Carlo | Pneumococcal vaccine |
| US4324887A (en) * | 1978-08-16 | 1982-04-13 | President And Fellows Of Harvard College | Type II group B Streptococci polysaccharide |
| FR2444464A1 (fr) * | 1978-12-19 | 1980-07-18 | Fabre Sa Pierre | Proteoglycanes bacteriens purifies, procede pour leur preparation et vaccin les contenant |
| US4242501A (en) * | 1979-08-08 | 1980-12-30 | American Cyanamid Company | Purification of pneumococcal capsular polysaccharides |
| US4287173A (en) * | 1979-09-24 | 1981-09-01 | Merck & Co., Inc. | Vaccine for dental caries |
| FR2471785A1 (fr) | 1979-12-21 | 1981-06-26 | Fabre Sa Pierre | Preparations immunostimulantes a base d'arn ribosomaux et procede de preparation des arn |
| FR2475900A1 (fr) * | 1980-02-20 | 1981-08-21 | Fabre Sa Pierre | Complexe vaccinal contenant un antigene specifique et vaccin le contenant |
| FR2495939B1 (fr) * | 1980-12-11 | 1985-10-11 | Merieux Inst | Procede de purification de polyosides de streptococcus pneumoniae et vaccin a base de polyosides ainsi purifies |
| BE889979A (fr) * | 1981-08-14 | 1982-02-15 | Smith Kline Rit | Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation |
| GB8906795D0 (en) * | 1989-03-23 | 1989-05-10 | Carroll Noel | Method of preparing vaccines |
| JPH0651347U (ja) * | 1992-12-21 | 1994-07-12 | 有限会社河上建築事務所 | 軒樋の枯葉止め |
| FR2703252B1 (fr) * | 1993-03-31 | 1996-09-06 | Fernand Narbey Torossian | Complexe immunomodulateur anti SIDA. |
| FR2790961B1 (fr) * | 1999-03-17 | 2001-06-22 | Fabre Pierre Sante | Utilisation d'une composition comprenant des proteoglycanes de klebsiella pneumoniae, et des ribosomes ou des arn ribosomaux bacteriens pour le traitement et/ou la prevention des maladies parodontales |
-
1977
- 1977-04-29 FR FR7713009A patent/FR2388563A1/fr active Granted
-
1978
- 1978-04-27 ES ES469225A patent/ES469225A1/es not_active Expired
- 1978-04-27 BE BE187182A patent/BE866464A/xx not_active IP Right Cessation
- 1978-04-28 IT IT49126/78A patent/IT1156717B/it active
- 1978-04-28 NL NL7804660A patent/NL7804660A/xx not_active Application Discontinuation
- 1978-04-28 CA CA302,203A patent/CA1103155A/fr not_active Expired
- 1978-04-28 DE DE19782818922 patent/DE2818922A1/de not_active Withdrawn
- 1978-04-28 GB GB16933/78A patent/GB1603340A/en not_active Expired
- 1978-04-28 CH CH469078A patent/CH630806A5/fr not_active IP Right Cessation
- 1978-05-01 JP JP5262378A patent/JPS53136516A/ja active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4141970A1 (de) * | 1991-12-16 | 1993-06-17 | Charite Med Fakultaet | Kombinationsimpfstoff gegen aids, bilharziose und tuberkulose und verfahren zu seiner herstellung |
| DE4141970C2 (de) * | 1991-12-16 | 1998-02-19 | Charite Med Fakultaet | Kombinationsimpfstoff gegen AIDS, Bilharziose und Tuberkulose und Verfahren zu seiner Herstellung |
| WO1997030171A1 (en) * | 1996-02-14 | 1997-08-21 | Merck & Co., Inc. | Polysaccharide precipitation process |
| US6410025B1 (en) | 1996-02-14 | 2002-06-25 | Merck & Co., Inc. | Polysaccharide precipitation process |
Also Published As
| Publication number | Publication date |
|---|---|
| IT7849126A0 (it) | 1978-04-28 |
| NL7804660A (nl) | 1978-10-31 |
| FR2388563B1 (es) | 1981-01-09 |
| CH630806A5 (en) | 1982-07-15 |
| JPS53136516A (en) | 1978-11-29 |
| CA1103155A (fr) | 1981-06-16 |
| ES469225A1 (es) | 1978-11-16 |
| GB1603340A (en) | 1981-11-25 |
| FR2388563A1 (fr) | 1978-11-24 |
| BE866464A (fr) | 1978-10-27 |
| IT1156717B (it) | 1987-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2818922A1 (de) | Verbesserte impfstoffe mit gehalt an kapselpolysacchariden | |
| DE2954387C2 (de) | Die tumorspezifische Immunität vergrößernder Bakterienzellenextrakt und Verfahren zu seiner Herstellung | |
| DE3875850T2 (de) | Verfahren zur gewinnung von polyosiden aus staphylokokken-kapseln sowie verwendungen dieser polyoside und staemme fuer die durchfuehrung dieses verfahrens. | |
| DE2331144A1 (de) | Wasserloesliche extrakte von mycobacterien | |
| US4596709A (en) | Novel immunostimulating glycoproteins | |
| DE2457090C2 (de) | Verfahren zur Herstellung von Impfstoffen sowie Antibronchialimpfstoff | |
| DE69012682T2 (de) | Verfahren zur Entfernung von bakteriellen Endotoxinen aus gram-negativen Polysacchariden. | |
| DE2833545A1 (de) | Hochmolekulare meningokokken- gruppe c-vaccine und verfahren zu ihrer herstellung | |
| DE3024282A1 (de) | Vakzinierende glycopeptid-antigenfraktion mit grosser immunisierungsfaehigkeit, isoliert aus kulturen pathogener keime, verfahren zur isolierung dieser fraktion und diese enthaltende vakzinen | |
| DE69026371T2 (de) | Heilmittel und verfahren zur inhibierung der vaskularisierung von tumoren | |
| DE3152621C2 (es) | ||
| DE3780843T2 (de) | Industrielles verfahren zur herstellung ribosomaler impfstoffe und die so erhaltenen ribosomalen impfstoffe. | |
| DE2723451C2 (es) | ||
| DE2357800A1 (de) | Verfahren zur herstellung von gammaglobulin | |
| DE1642676A1 (de) | Verfahren zur Reinigung von Lipopolysacchariden | |
| DE1620639A1 (de) | Verfahren zur Herstellung von 9-ss-D-Ribofuranosyl-7-deazapurin-3',5'-cyclophosphaten | |
| DE2613943C3 (de) | Herstellung von Vaeeinen auf Ribonucleinsäurebasis | |
| DE3716669A1 (de) | Verfahren zur herstellung von zellwandkomponenten aus archaebakterien und deren verwendung als arzneimittel | |
| JPH0742322B2 (ja) | クレブシェラ属細菌のアシルグリカン、その製造方法及びそれからなる薬剤 | |
| DE3789186T2 (de) | Methode zur Isolierung und Reinigung von Amylasen und Adsorbentien, sowie Vorrichtungen zur Isolierung und Reinigung. | |
| DE3873139T2 (de) | Derivat von d.25, verfahren zur herstellung, verwendung als immunostimulierendes mittel und pharmazeutische zusammensetzungen, welche diese enthalten. | |
| DE936594C (de) | Verfahren zur Herstellung von Dextranabbauprodukten fuer pharmazeutische Zwecke | |
| DE1959603A1 (de) | Kristalline Kombination aus L-Asparaginase und einem Metall- oder Metalloidion und Verfahren zu ihrer Herstellung | |
| AT224807B (de) | Verfahren zur Gewinnung eines neuen tumorhemmenden Polysaccharids | |
| DE1070176B (de) | Verfahren zur Herstellung neuer Steroidverbindungen der 1, 4 - Pregnadienreihe |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8141 | Disposal/no request for examination | ||
| 8127 | New person/name/address of the applicant |
Owner name: P.F. MEDICAMENT S.A., PARIS, FR |
|
| 8128 | New person/name/address of the agent |
Representative=s name: BARTELS, H. HELD, M., DIPL.-ING. DR.-ING. FINK, H. |